NCT06113744View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine

PHASE1RecruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2024

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Placebo

saline

BIOLOGICAL

COVID-19 Vaccine (Vero Cell) ,Inactivated

COVILO

BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 10 μg

Low-dose

BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 30 μg

Mid-dose

BIOLOGICAL

COVID-19 mRNA Vaccine (ZSVG-02-O) 60 μg

High-dose

Trial Locations (1)

Unknown

RECRUITING

Shulan (Hangzhou) Hospital, Hangzhou

All Listed Sponsors
collaborator

Shulan (Hangzhou) Hospital

OTHER

lead

CNBG-Virogin Biotech (Shanghai) Ltd.

INDUSTRY